Buditerm F 12 Inhaler: Your Premier PCD Pharma Franchise in Pulmonology

About Budesonide + Formoterol: A Synergistic Therapy for Asthma and COPD

Tapping into the High-Demand Market of Chronic Respiratory Disorders

Why Buditerm F 12 Inhaler is a High-Profit Opportunity for Distributors

Partnering for Success with a Quality-Assured Product
Join Our Pharma Franchise for Unmatched Business Support

Home/Products /budesonide-400-mcg-formoterol-fumarate-12-mcg-inhaler

About the Product

Description


Buditerm F 12 Inhaler is an advanced and highly effective combination medication that provides powerful, dual-action therapy for the long-term management of chronic respiratory diseases. It contains a precise dose of Budesonide (400 mcg), a potent inhaled corticosteroid, and Formoterol Fumarate (12 mcg), a fast-acting, long-lasting bronchodilator. This strategic ICS-LABA combination works synergistically to address both the underlying inflammation in the airways and the immediate bronchospasm, offering a level of control and symptom prevention that is superior to monotherapy. It is an essential component of daily maintenance therapy for patients with moderate to severe asthma and COPD.

The respiratory segment of the Indian pharmaceutical market is a high-volume, high-value sector with a consistently high demand. The rising prevalence of respiratory disorders, fueled by factors such as increasing air pollution, smoking, and an aging population, ensures a continuous need for advanced maintenance therapies. Products like Buditerm F 12 Inhaler represent a premium category in the pulmonology segment, with a stable prescription base from specialists. This makes it a strategic choice for any distributor seeking a stable and profitable business, as its essential nature guarantees a steady and predictable revenue stream.

We are dedicated to empowering our franchise partners with all the tools necessary for success. Our product, manufactured in a WHO-GMP certified facility, ensures impeccable quality, efficacy, and safety, which is crucial for building trust with healthcare professionals and patients. We provide a complete promotional and marketing kit, including visual aids and product literature, to support your sales efforts. Our robust supply chain guarantees timely delivery and continuous stock availability, preventing any business interruptions. Partner with us to enter this stable and highly profitable market and establish a reputable and successful business as a key supplier of this top-quality respiratory medicine.

May include hoarseness, throat irritation, dry mouth, or cough. Long-term use can rarely lead to oral thrush (fungal infection). Rinse mouth after each use to prevent this.

Persistent asthma (mild to severe) Chronic obstructive pulmonary disease (COPD) Allergic and non-allergic airway inflammation Nebulization therapy in children and adults as prescribed

Use only with a nebulizer under medical supervision. Not for acute asthma attacks – use a rescue inhaler for quick relief. Rinse mouth after inhalation to prevent infections. Regular use is important for effectiveness – do not skip doses. Do not stop suddenly without consulting your doctor.

Store below 25°C. Protect from light and moisture. Do not freeze. Keep out of reach of children. Use immediately after opening the respule.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Budesonide 400 mcg + Formoterol Fumarate 12 mcg Inhaler in the PCD pharma franchise market?

This combination inhaler has strong demand in the respiratory and pulmonology segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners focusing on asthma and COPD management portfolios.

Why should medical distributors include this inhaler in their product range?

Medical distributors and agencies can benefit from consistent demand for long-term management of asthma, chronic obstructive pulmonary disease (COPD), wheezing, and breathlessness episodes. Budesonide reduces airway inflammation (inhaled corticosteroid) Formoterol is a long-acting bronchodilator that relaxes airway muscles Together, they provide dual action control (maintenance + symptom relief), strengthening a reliable respiratory care portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for this inhaler with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong pulmonologist prescriptions, high chronic respiratory demand, long-term daily usage, hospital and emergency clinic supply, reliable supply chain support, and good margins in respiratory inhalation therapy products.

How can I become a distributor or franchise partner for this inhaler?

Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, territory rights, and distribution opportunities.